Gurugram, February 3, 2025 – Dhanuka Agritech Limited (NSE: DHANUKA, BSE: 507717), a leading agrochemical company, announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024. The company reported robust growth in revenues and profits, supported by strategic international expansion and share buyback initiatives.
Key Financial Highlights (Standalone)
(All figures in ₹ Lakhs)| Particulars | Q3 FY25 | Q2 FY25 | Q3 FY24 | 9M FY25 | 9M FY24 | FY24 (Audited) |
|---|---|---|---|---|---|---|
| Revenue from Operations | 44,527.21 | 65,427.84 | 40,324.42 | 1,59,312.86 | 1,39,023.23 | 1,75,854.39 |
| Total Income | 45,228.53 | 66,507.97 | 41,052.31 | 1,61,807.79 | 1,40,991.26 | 1,79,350.47 |
| Total Expenses | 38,420.86 | 50,842.10 | 35,469.73 | 1,32,759.96 | 1,17,265.36 | 1,47,475.03 |
| Profit Before Tax (PBT) | 6,807.67 | 15,665.87 | 5,582.58 | 29,047.83 | 23,725.90 | 31,875.44 |
| Net Profit (PAT) | 5,504.47 | 11,751.82 | 4,536.90 | 22,145.80 | 18,007.71 | 23,909.27 |
| Earnings Per Share (EPS) – Basic & Diluted (₹) | 12.25 | 25.83 | 9.95 | 48.81 | 39.51 | 52.46 |
Segment Performance and Key Developments
- International Expansion:
- The company signed agreements with Bayer AG, Germany, to acquire international rights for two active ingredients—Iprovalicarb and Triadimenol.
- This move is set to expand Dhanuka's presence in over 20 countries, including LATAM, EMEA, and Asia (including India).
- Buyback of Equity Shares:
- 500,000 fully paid-up equity shares (1.10% of total share capital) were bought back at ₹2,000 per share, amounting to ₹100 crores.
- The extinguishment of these shares on September 11, 2024, resulted in a paid-up capital reduction.
- Financial Stability & Taxation:
- Current tax expenses stood at ₹1,919 lakh in Q3 FY25, compared to ₹1,451.69 lakh in Q3 FY24, reflecting increased profitability.
- Deferred tax adjustments resulted in an effective tax rate management strategy.
Consolidated Financial Performance
The consolidated results remained consistent with standalone figures, as the company's wholly-owned subsidiary, Dhanuka Chemicals Private Limited, was officially struck off on July 16, 2024. The consolidated PAT remained at ₹5,504.47 lakh for Q3 FY25, aligning with standalone performance.Management Commentary
M.K. Dhanuka, Chairman, Dhanuka Agritech Limited, stated: "Our strong Q3 results reflect our commitment to expanding Dhanuka’s footprint in global markets while enhancing shareholder value through strategic acquisitions and capital restructuring. The acquisition of Iprovalicarb and Triadimenol will strengthen our international presence, and we remain optimistic about sustained growth in the coming quarters."Strategic Outlook
- International Growth: Expansion into LATAM, EMEA, and Asia through Bayer AG's active ingredient acquisition.
- R&D Investments: Focus on developing innovative crop protection solutions to address evolving agricultural challenges.
- Domestic Market Trends: Given the seasonal nature of agrochemical demand, the company expects strong performance in upcoming quarters, influenced by monsoon patterns and pest infestation cycles.
Investor Perspective
Dhanuka Agritech's growth trajectory remains promising, with:
Revenue expansion (+10.4% YoY) Higher profitability (+21.4% YoY PAT growth) Strategic acquisitions & international expansion Shareholder value enhancement via share buybackInvestors may find Dhanuka Agritech well-positioned for long-term growth, backed by its robust financial health, operational efficiency, and strategic global expansion initiatives.